102 related articles for article (PubMed ID: 18174751)
1. Long-acting forms of growth hormone-releasing hormone and growth hormone: effects in normal volunteers and adults with growth hormone deficiency.
Clemmons DR
Horm Res; 2007; 68 Suppl 5():178-81. PubMed ID: 18174751
[TBL] [Abstract][Full Text] [Related]
2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Ionescu M; Frohman LA
J Clin Endocrinol Metab; 2006 Dec; 91(12):4792-7. PubMed ID: 17018654
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
4. GHRH and GH secretagogues: clinical perspectives and safety.
Aimaretti G; Baldelli R; Corneli G; Bellone S; Rovere S; Croce C; Ragazzoni F; Giordano R; Arvat E; Bona G; Ghigo E
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():86-92. PubMed ID: 16456487
[TBL] [Abstract][Full Text] [Related]
5. Repetitive injections of growth hormone releasing hormone (GHRH1-44) to normal volunteers and patients with growth hormone deficiency.
Hümmelink R; Sippell WG
Horm Metab Res; 1990 Feb; 22(2):101-8. PubMed ID: 2182500
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone releasing hormone plus arginine stimulation testing in young adults treated in childhood with cranio-spinal radiation therapy.
Ham JN; Ginsberg JP; Hendell CD; Moshang T
Clin Endocrinol (Oxf); 2005 May; 62(5):628-32. PubMed ID: 15853837
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
[TBL] [Abstract][Full Text] [Related]
10. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL; Neale A; Lawrence B; Gagnon C; Castaigne JP; Frohman LA
J Clin Endocrinol Metab; 2006 Mar; 91(3):799-805. PubMed ID: 16352683
[TBL] [Abstract][Full Text] [Related]
11. Liquid growth hormone: preservatives and buffers.
Kappelgaard AM; Bojesen A; Skydsgaard K; Sjögren I; Laursen T
Horm Res; 2004; 62 Suppl 3():98-103. PubMed ID: 15539807
[TBL] [Abstract][Full Text] [Related]
12. Status of long-acting-growth hormone preparations--2015.
Høybye C; Cohen P; Hoffman AR; Ross R; Biller BM; Christiansen JS;
Growth Horm IGF Res; 2015 Oct; 25(5):201-6. PubMed ID: 26187188
[TBL] [Abstract][Full Text] [Related]
13. Novel long-acting GH preparations.
Doknic M; Stojanovic M; Popovic V
Pediatr Endocrinol Rev; 2014 Dec; 12(2):206-12. PubMed ID: 25581986
[TBL] [Abstract][Full Text] [Related]
14. Cortical bone density is normal in prepubertal children with growth hormone (GH) deficiency, but initially decreases during gh replacement due to early bone remodeling.
Baroncelli GI; Bertelloni S; Galli L; Sodini F; Saggese G
J Clin Endocrinol Metab; 2004 May; 89(5):2505; author reply 2505-6. PubMed ID: 15126585
[No Abstract] [Full Text] [Related]
15. Developing long-acting growth hormone formulations.
Cawley P; Wilkinson I; Ross RJ
Clin Endocrinol (Oxf); 2013 Sep; 79(3):305-9. PubMed ID: 23662913
[TBL] [Abstract][Full Text] [Related]
16. Short-term tools to measure responsiveness to growth hormone replacement.
Jørgensen JO; Hansen TK; Conceição FL; Christensen JJ; Vahl N; Christiansen JS
Horm Res; 2001; 55 Suppl 2():40-3. PubMed ID: 11684875
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.
Miller BS; Velazquez E; Yuen KCJ
J Clin Endocrinol Metab; 2020 Jun; 105(6):e2121-33. PubMed ID: 31676901
[TBL] [Abstract][Full Text] [Related]
18. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks.
Höybye C
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101788. PubMed ID: 37308376
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sustained-release recombinant human growth hormone in Korean adults with growth hormone deficiency.
Kim Y; Hong JW; Chung YS; Kim SW; Cho YW; Kim JH; Kim BJ; Lee EJ
Yonsei Med J; 2014 Jul; 55(4):1042-8. PubMed ID: 24954335
[TBL] [Abstract][Full Text] [Related]
20. The current state of long-acting growth hormone preparations for growth hormone therapy.
Yuen KCJ; Miller BS; Biller BMK
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):267-273. PubMed ID: 29746309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
